AKT1 and neoplasm: Moreover, for those resistant to kinase inhibitors, such as K-RAS-mutant lung cancers, the combination of DT-061 and the MEK inhibitor AZD6244 leads to suppression of the AKT and MYC pathways and attenuation of tumor growth 172.